<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">67023</article-id><article-id pub-id-type="doi">10.7554/eLife.67023</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Epidemiology and Global Health</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Impact of COVID-19-related disruptions to measles, meningococcal A, and yellow fever vaccination in 10 countries</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-132939"><name><surname>Gaythorpe</surname><given-names>Katy A M</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3734-9081</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-225967"><name><surname>Abbas</surname><given-names>Kaja</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-224199"><name><surname>Huber</surname><given-names>John</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5245-5187</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-225961"><name><surname>Karachaliou</surname><given-names>Andromachi</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-225968"><name><surname>Thakkar</surname><given-names>Niket</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-225969"><name><surname>Woodruff</surname><given-names>Kim</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-225970"><name><surname>Li</surname><given-names>Xiang</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-225971"><name><surname>Echeverria-Londono</surname><given-names>Susy</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><collab>VIMC Working Group on COVID-19 Impact on Vaccine Preventable Disease</collab></contrib><contrib contrib-type="author" id="author-225973"><name><surname>Ferrari</surname><given-names>Matthew</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-137146"><name><surname>Jackson</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-225974"><name><surname>McCarthy</surname><given-names>Kevin</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-128653"><name><surname>Perkins</surname><given-names>Alex T</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7518-4014</contrib-id><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-58531"><name><surname>Trotter</surname><given-names>Caroline</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" corresp="yes" id="author-1708"><name><surname>Jit</surname><given-names>Mark</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6658-8255</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf5"/></contrib><aff id="aff1"><institution content-type="dept">MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology</institution>, <institution>Imperial College London</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>Switzerland</country></aff><aff id="aff2"><institution content-type="dept">Department of Infectious Disease Epidemiology</institution>, <institution>London School of Hygiene &amp; Tropical Medicine</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff3"><institution>University of Notre Dame</institution>, <addr-line><named-content content-type="city">Notre Dame</named-content></addr-line>, <country>France</country></aff><aff id="aff4"><institution content-type="dept">Department of Vetinary Medicine</institution>, <institution>University of Cambridge</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff5"><institution content-type="dept">Institute for Disease Modelling</institution>, <institution>Institute for Disease Modelling</institution>, <addr-line><named-content content-type="city">Seattle</named-content></addr-line>, <country>United States</country></aff><aff id="aff6"><institution content-type="dept">MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology</institution>, <institution>Imperial College London</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff7"><institution content-type="dept">Department of Biology</institution>, <institution>Pennsylvania State University</institution>, <addr-line><named-content content-type="city">University Park</named-content></addr-line>, <country>United States</country></aff><aff id="aff8"><institution>Kaiser Permanente Washington,</institution>, <addr-line><named-content content-type="city">Seattle</named-content></addr-line>, <country>United States</country></aff><aff id="aff9"><institution>University of Notre Dame</institution>, <addr-line><named-content content-type="city">Notre Dame</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-183731"><name><surname>Malagón</surname><given-names>Talía</given-names></name><role>Reviewing editor</role><aff><institution>McGill University</institution>, <country>Canada</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>Mark.Jit@lshtm.ac.uk</email> (MJ);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>24</day><month>06</month><year>2021</year></pub-date><volume>10</volume><elocation-id>e67023</elocation-id><history><date date-type="received"><day>29</day><month>01</month><year>2021</year></date><date date-type="accepted"><day>23</day><month>06</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Gaythorpe et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Gaythorpe et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-67023-v2.pdf"/><abstract><p><bold>Background:</bold> Childhood immunisation services have been disrupted by COVID-19. WHO recommends considering outbreak risk using epidemiological criteria when deciding whether to conduct preventive vaccination campaigns during the pandemic. </p><p><bold>Methods:</bold> We used 2-3 models per infection to estimate the health impact of 50% reduced routine vaccination coverage and delaying campaign vaccination for measles, meningococcal A and yellow fever vaccination in 3-6 high burden countries per infection. </p><p><bold>Results:</bold> Reduced routine coverage in 2020 without catch-up vaccination may increase measles and yellow fever disease burden in the modelled countries. Delaying planned campaigns may lead to measles outbreaks and increases in yellow fever burden in some countries. For meningococcal A vaccination, short term disruptions in 2020 are unlikely to have a significant impact. </p><p><bold>Conclusion:</bold> The impact of COVID-19-related disruption to vaccination programs varies between infections and countries. </p><p><bold>Funding:</bold> Bill and Melinda Gates Foundation and Gavi, the Vaccine Alliance.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution>Gavi, the Vaccine Alliance and the Bill &amp; Melinda Gates Foundation</institution></institution-wrap></funding-source><award-id>OPP1157270 and INV-016832</award-id><principal-award-recipient><name><surname>Gaythorpe</surname><given-names>Katy A M</given-names></name><name><surname>Abbas</surname><given-names>Kaja</given-names></name><name><surname>Huber</surname><given-names>John</given-names></name><name><surname>Karachaliou</surname><given-names>Andromachi</given-names></name><name><surname>Thakkar</surname><given-names>Niket</given-names></name><name><surname>Woodruff</surname><given-names>Kim</given-names></name><name><surname>Li</surname><given-names>Xiang</given-names></name><name><surname>Echeverria-Londono</surname><given-names>Susy</given-names></name><name><surname>Ferrari</surname><given-names>Matthew</given-names></name><name><surname>Jackson</surname><given-names>Michael</given-names></name><name><surname>McCarthy</surname><given-names>Kevin</given-names></name><name><surname>Perkins</surname><given-names>Alex T</given-names></name><name><surname>Trotter</surname><given-names>Caroline</given-names></name><name><surname>Jit</surname><given-names>Mark</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Niket Thakkar, KM is an employee of the Institute for Disease Modeling at the Bill &amp; Melinda Gates Foundation, which funded the research..</p></fn><fn fn-type="conflict" id="conf3"><p>Michael Jackson, KM is an employee of the Institute for Disease Modeling at the Bill &amp; Melinda Gates Foundation, which funded the research..</p></fn><fn fn-type="conflict" id="conf4"><p>Caroline Trotter, CT declares a consultancy fee from GSK in 2018 (unrelated to the submitted work)..</p></fn><fn fn-type="conflict" id="conf5"><p>Mark Jit, Reviewing editor, <italic>eLife</italic>.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All code, data inputs and outputs used to generate the results in the manuscript (apart from projections about vaccine coverage beyond 2020 which are commercially confidential property of Gavi) are available at: https://github.com/vimc/vpd-covid-phase-I.</p></sec><supplementary-material><ext-link xlink:href="elife-67023-supp-v2.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>